Previous Close | 2.0000 |
Open | N/A |
Bid | 0.9000 |
Ask | 3.7000 |
Strike | 22.00 |
Expire Date | 2022-08-19 |
Day's Range | 2.0000 - 2.0000 |
Contract Range | N/A |
Volume | |
Open Interest | 20 |
2021 report demonstrates focus on ESG initiatives supporting health equity, social justice, and sustainability SALT LAKE CITY, June 28, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today released its first environmental, social and governance (ESG) report, highlighting increased efforts to support a healthy, equitable and sustainable society. The report outlines actions taken to expand access to genetic testing, advance socia
Myriad Genetics (MYGN) continues to benefit from strong testing volumes, but forex remains a woe.
Healthcare providers can easily order Myriad’s genetic tests for the more than 250 million patients within Epic’s networkPartnership bolsters Myriad’s growth plan to scale customer-centric, tech-enabled commercial capabilities with over 600 EHR integrations this year SALT LAKE CITY, June 23, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a partnership with Epic, the industry leading healthcare software company,